MA50391A - Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires - Google Patents

Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires

Info

Publication number: MA50391A
Authority: MA; Morocco
Prior art keywords: treatment; pharmaceutical compositions; new compounds; inflammatory disorders; associated pharmaceutical
Prior art date: 2017-10-20

Application number

MA050391A

Other languages

English (en)

Other versions

MA50391B1 (fr

Inventor

David Amantini

Denis Maurice Annoot

Reginald Christophe Xavier Brys

Pieter Isabelle Roger Claes

Ghjuvanni Petru Diunisu Coti

René Alexandre Galien

Ramos Miriam López

Oscar Mammoliti

Sébastien Laurent Xavier Martina

Der Plas Steven Emiel Van

Original Assignee

Galapagos Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-20

Filing date

2018-10-11

Publication date

2021-04-21

2018-10-11 Application filed by Galapagos Nv filed Critical Galapagos Nv

2021-04-21 Publication of MA50391A publication Critical patent/MA50391A/fr

2023-11-30 Publication of MA50391B1 publication Critical patent/MA50391B1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MA50391A 2017-10-20 2018-10-11 Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires MA50391B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1717260.2A GB201717260D0 (en)	2017-10-20	2017-10-20	Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2018/077677 WO2019076716A1 (fr)	2017-10-20	2018-10-11	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires

Publications (2)

Publication Number	Publication Date
MA50391A true MA50391A (fr)	2021-04-21
MA50391B1 MA50391B1 (fr)	2023-11-30

Family

ID=60481889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA50391A MA50391B1 (fr)	2017-10-20	2018-10-11	Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires

Country Status (31)

Country	Link
US (2)	US11564923B2 (fr)
EP (2)	EP4265254A3 (fr)
JP (2)	JP7292271B2 (fr)
KR (1)	KR102757425B1 (fr)
CN (2)	CN117534670A (fr)
AR (1)	AR113784A1 (fr)
AU (2)	AU2018350592B2 (fr)
BR (1)	BR112020007541A2 (fr)
CA (1)	CA3079449A1 (fr)
CO (1)	CO2020005200A2 (fr)
DK (1)	DK3697784T5 (fr)
ES (1)	ES2967432T3 (fr)
FI (1)	FI3697784T5 (fr)
GB (1)	GB201717260D0 (fr)
HR (1)	HRP20231315T1 (fr)
HU (1)	HUE063998T2 (fr)
IL (2)	IL273943B2 (fr)
LT (1)	LT3697784T (fr)
MA (1)	MA50391B1 (fr)
MX (1)	MX2020003863A (fr)
MY (1)	MY205443A (fr)
PH (1)	PH12020550230A1 (fr)
PL (1)	PL3697784T3 (fr)
PT (1)	PT3697784T (fr)
RS (1)	RS64800B1 (fr)
SG (1)	SG11202003516TA (fr)
SI (1)	SI3697784T1 (fr)
SM (1)	SMT202300377T1 (fr)
TW (2)	TWI866258B (fr)
WO (1)	WO2019076716A1 (fr)
ZA (1)	ZA202002166B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201717260D0 (en) *	2017-10-20	2017-12-06	Galapagos Nv	Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
WO2020240586A1 (fr) *	2019-05-28	2020-12-03	Mankind Pharma Ltd.	Nouveaux composés pour l'inhibition de la janus kinase 1
EP4294808A1 (fr)	2021-02-19	2023-12-27	Sudo Biosciences Limited	Inhibiteurs de tyk2 et leurs utilisations
JP2024508794A (ja)	2021-02-19	2024-02-28	スドーバイオサイエンシーズリミテッド	Ｔｙｋ２阻害剤およびその使用
JP2024524631A (ja)	2021-07-12	2024-07-05	ガラパゴス・ナムローゼ・フェンノートシャップ	炎症性疾患の治療
JP2025503448A (ja)	2021-12-16	2025-02-04	リンクファーマシューティカルズシーオー．エルティーディー．	Ｔｙｋ２阻害剤および組成物ならびにその方法
WO2023161327A1 (fr) *	2022-02-24	2023-08-31	Galapagos Nv	Procédés de traitement de maladies inflammatoires et composé destiné à être utilisé dans ces procédés
WO2023161326A1 (fr)	2022-02-24	2023-08-31	Galapagos Nv	Procédés de traitement de maladies inflammatoires et composé destiné à être utilisé dans ces procédés
JP2024082106A (ja) *	2022-12-07	2024-06-19	富士通株式会社	情報処理プログラム、情報処理方法および情報処理装置
PE20252285A1 (es)	2023-01-18	2025-09-18	Galapagos Nv	Composiciones farmaceuticas para el tratamiento de trastornos inflamatorios
WO2024153618A1 (fr)	2023-01-19	2024-07-25	Galapagos Nv	Dérivés d'imidazo[4,5-b]pyridine utiles pour le traitement de maladies allergiques, de maladies inflammatoires, de maladies métaboliques, de maladies auto-inflammatoires, de maladies auto-immunes et de maladies prolifératives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2251341A1 (fr) *	2005-07-14	2010-11-17	Astellas Pharma Inc.	Hétérocycles inhibiteurs de Janus kinase-3
UA99459C2 (en)	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
ES2567552T3 (es) *	2012-01-30	2016-04-25	Cephalon, Inc.	Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
GB201401086D0 (en) *	2014-01-23	2014-03-12	Galapagos Nv	Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2017012647A1 (fr)	2015-07-20	2017-01-26	Galapagos Nv	Nouveaux composés et compositions pharmaceutiques les comprenant pour le traitement de troubles inflammatoires
AR105400A1 (es)	2015-08-04	2017-09-27	Lilly Co Eli	Inhibidores de jak1
IL266109B2 (en) *	2016-10-21	2025-05-01	Nimbus Lakshmi Inc	Tyk2 inhibitors and uses thereof
GB201717260D0 (en) *	2017-10-20	2017-12-06	Galapagos Nv	Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

2017
- 2017-10-20 GB GBGB1717260.2A patent/GB201717260D0/en not_active Ceased
2018
- 2018-10-11 IL IL273943A patent/IL273943B2/en unknown
- 2018-10-11 MY MYPI2020001882A patent/MY205443A/en unknown
- 2018-10-11 SG SG11202003516TA patent/SG11202003516TA/en unknown
- 2018-10-11 PL PL18788711.2T patent/PL3697784T3/pl unknown
- 2018-10-11 HU HUE18788711A patent/HUE063998T2/hu unknown
- 2018-10-11 BR BR112020007541-8A patent/BR112020007541A2/pt active Search and Examination
- 2018-10-11 SI SI201831002T patent/SI3697784T1/sl unknown
- 2018-10-11 JP JP2020521991A patent/JP7292271B2/ja active Active
- 2018-10-11 CN CN202311478101.5A patent/CN117534670A/zh active Pending
- 2018-10-11 US US16/757,189 patent/US11564923B2/en active Active
- 2018-10-11 MX MX2020003863A patent/MX2020003863A/es unknown
- 2018-10-11 KR KR1020207014284A patent/KR102757425B1/ko active Active
- 2018-10-11 RS RS20231045A patent/RS64800B1/sr unknown
- 2018-10-11 SM SM20230377T patent/SMT202300377T1/it unknown
- 2018-10-11 CA CA3079449A patent/CA3079449A1/fr active Pending
- 2018-10-11 AU AU2018350592A patent/AU2018350592B2/en active Active
- 2018-10-11 CN CN201880067863.7A patent/CN111225916B/zh active Active
- 2018-10-11 FI FIEP18788711.2T patent/FI3697784T5/fi active
- 2018-10-11 DK DK18788711.2T patent/DK3697784T5/da active
- 2018-10-11 IL IL302615A patent/IL302615B2/en unknown
- 2018-10-11 PT PT187887112T patent/PT3697784T/pt unknown
- 2018-10-11 EP EP23191626.3A patent/EP4265254A3/fr active Pending
- 2018-10-11 LT LTEPPCT/EP2018/077677T patent/LT3697784T/lt unknown
- 2018-10-11 WO PCT/EP2018/077677 patent/WO2019076716A1/fr not_active Ceased
- 2018-10-11 ES ES18788711T patent/ES2967432T3/es active Active
- 2018-10-11 HR HRP20231315TT patent/HRP20231315T1/hr unknown
- 2018-10-11 EP EP18788711.2A patent/EP3697784B9/fr active Active
- 2018-10-11 MA MA50391A patent/MA50391B1/fr unknown
- 2018-10-19 TW TW112121026A patent/TWI866258B/zh active
- 2018-10-19 TW TW107136998A patent/TWI805629B/zh active
- 2018-10-19 AR ARP180103068A patent/AR113784A1/es unknown
2020
- 2020-04-07 PH PH12020550230A patent/PH12020550230A1/en unknown
- 2020-04-27 CO CONC2020/0005200A patent/CO2020005200A2/es unknown
- 2020-05-04 ZA ZA2020/02166A patent/ZA202002166B/en unknown
2022
- 2022-12-27 US US18/146,698 patent/US12472181B2/en active Active
2023
- 2023-03-10 AU AU2023201522A patent/AU2023201522B2/en active Active
- 2023-06-06 JP JP2023093474A patent/JP7654031B2/ja active Active

Also Published As

Publication number	Publication date
AU2018350592B2 (en)	2022-12-22
EP3697784B1 (fr)	2023-10-04
PH12020550230A1 (en)	2021-02-08
IL302615B1 (en)	2024-06-01
TW202411229A (zh)	2024-03-16
TWI866258B (zh)	2024-12-11
KR102757425B1 (ko)	2025-01-20
IL273943B1 (en)	2023-06-01
SG11202003516TA (en)	2020-05-28
AU2018350592A1 (en)	2020-06-04
US11564923B2 (en)	2023-01-31
MA50391B1 (fr)	2023-11-30
RU2020116376A (ru)	2021-11-22
CN111225916A (zh)	2020-06-02
CN117534670A (zh)	2024-02-09
JP7292271B2 (ja)	2023-06-16
DK3697784T3 (da)	2023-10-30
FI3697784T5 (fi)	2024-01-12
AR113784A1 (es)	2020-06-10
CO2020005200A2 (es)	2020-05-29
LT3697784T (lt)	2023-10-25
IL302615A (en)	2023-07-01
HUE063998T2 (hu)	2024-02-28
US12472181B2 (en)	2025-11-18
ES2967432T3 (es)	2024-04-30
TWI805629B (zh)	2023-06-21
AU2023201522A1 (en)	2023-04-13
EP3697784A1 (fr)	2020-08-26
SMT202300377T1 (it)	2024-01-10
EP3697784B9 (fr)	2023-12-27
MX2020003863A (es)	2020-08-13
HRP20231315T1 (hr)	2024-02-16
US20210169879A1 (en)	2021-06-10
KR20200074178A (ko)	2020-06-24
ZA202002166B (en)	2021-05-26
RU2020116376A3 (fr)	2021-11-22
JP2023113834A (ja)	2023-08-16
JP2020537672A (ja)	2020-12-24
AU2023201522B2 (en)	2024-11-28
BR112020007541A2 (pt)	2020-09-24
US20230310433A1 (en)	2023-10-05
FI3697784T3 (fi)	2023-10-31
IL273943B2 (en)	2023-10-01
PL3697784T3 (pl)	2024-03-11
IL273943A (en)	2020-05-31
CN111225916B (zh)	2023-11-03
SI3697784T1 (sl)	2023-11-30
DK3697784T5 (da)	2024-01-15
EP4265254A3 (fr)	2024-03-13
RS64800B1 (sr)	2023-11-30
CA3079449A1 (fr)	2019-04-25
JP7654031B2 (ja)	2025-03-31
MY205443A (en)	2024-10-22
EP4265254A2 (fr)	2023-10-25
PT3697784T (pt)	2024-01-09
WO2019076716A1 (fr)	2019-04-25
IL302615B2 (en)	2024-10-01
TW201918483A (zh)	2019-05-16
GB201717260D0 (en)	2017-12-06

Publication	Publication Date	Title
MA51200A (fr)	2020-10-07	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA50391A (fr)	2021-04-21	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA51739A (fr)	2020-12-16	Compositions pharmaceutiques pour le traitement de la fibrose kystique
MA56019A (fr)	2022-04-06	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52873A (fr)	2021-04-21	Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3704108A4 (fr)	2021-08-25	Composés et compositions pour le traitement de troubles hématologiques
EP3340982A4 (fr)	2019-03-27	Composés pour le traitement de troubles immunitaires et inflammatoires
EP3448398A4 (fr)	2019-12-18	Compositions et méthodes pour le traitement de troubles cutanés
LU92577B1 (fr)	2015-02-24	Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
MA55497A (fr)	2022-02-09	Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
LU92578B1 (fr)	2014-12-15	Nouveaux composés et compostions pharmaceutiques de ceux-ci pour le traitement de la mucoviscidose
EP3328376A4 (fr)	2019-03-13	Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique
EP3328864A4 (fr)	2019-01-09	Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
MA52118A (fr)	2021-05-19	Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose
EP3500267A4 (fr)	2020-03-18	Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
MA44875A (fr)	2019-03-13	Compositions pour le traitement de troubles acido-basiques
MA44737A (fr)	2021-04-07	Compositions pour le traitement de troubles liés à l'hyperkératose
EP3890747A4 (fr)	2022-08-03	Compositions pour le traitement de la fibrose et de l'inflammation
MA51056A (fr)	2020-10-14	Compositions et méthodes pour le traitement d'affections métaboliques
EP3841086A4 (fr)	2022-07-27	Composés pharmaceutiques pour le traitement de troubles médicaux du facteur d du complément
EP3352749A4 (fr)	2019-09-04	Composés et compositions pour le traitement de troubles oculaires
EP3368088C0 (fr)	2023-06-07	Compositions et méthodes pour le traitement de troubles du peroxisome et de leucodystrophies
EP3661553A4 (fr)	2021-06-02	Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes
MA47207A (fr)	2019-11-13	Composés utiles pour le traitement de troubles du tractus digestif
EP3723768A4 (fr)	2021-09-01	Composés pour le traitement et la prévention de pathologies médiées par l'histone extracellulaire